Brenntag SE (0MPT.IL)
IOB - IOB Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
Al 10:28AM GMT. Mercato aperto.
| Chiusura precedente | 68,00 |
| Aperto | 67,68 |
| Denaro | 66,36 x 0 |
| Lettera | 67,76 x 0 |
| Min-Max giorno | 66,70 - 67,80 |
| Intervallo di 52 settimane | 53,64 - 76,38 |
| Volume | |
| Media Volume | 240.968 |
| Capitalizzazione | 10,41B |
| Beta (5 anni mensile) | 1,06 |
| Rapporto PE (ttm) | 20,76 |
| EPS (ttm) | 3,23 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | 1,45 (2,08%) |
| Data ex dividendo | 10 giu 2022 |
| Stima target 1A | N/D |
- GlobeNewswire
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting
BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that collaborator Brahm Segal, M.D., of Roswell Park Comprehensive Cancer Center shared nonclinical data from a research study that models the ability of NC410 to block neutrophil-mediated suppression of T cells in a tumor microen
© 2023 Yahoo. Tutti i diritti riservati.
